Association Between ABCB1 Polymorphism and Stable Warfarin Dose Requirements in Brazilian Patients by Tavares, Leticia C. et al.
ORIGINAL RESEARCH
published: 23 May 2018
doi: 10.3389/fphar.2018.00542
Frontiers in Pharmacology | www.frontiersin.org 1 May 2018 | Volume 9 | Article 542
Edited by:
Rick Kittles,
Irell and Manella Graduate School of
Biological Sciences, City of Hope,
United States
Reviewed by:
Jason Hansen Karnes,
University of Arizona, United States
Adam P. Bress,
University of Utah, United States
*Correspondence:
Paulo C. J. L. Santos
paulo.caleb@unifesp.br
Specialty section:
This article was submitted to
Pharmacogenetics and
Pharmacogenomics,
a section of the journal
Frontiers in Pharmacology
Received: 15 March 2018
Accepted: 04 May 2018
Published: 23 May 2018
Citation:
Tavares LC, Marcatto LR,
Soares RAG, Krieger JE, Pereira AC
and Santos PCJL (2018) Association
Between ABCB1 Polymorphism and
Stable Warfarin Dose Requirements in
Brazilian Patients.
Front. Pharmacol. 9:542.
doi: 10.3389/fphar.2018.00542
Association Between ABCB1
Polymorphism and Stable Warfarin
Dose Requirements in Brazilian
Patients
Letícia C. Tavares 1, Leiliane R. Marcatto 1, Renata A. G. Soares 1, Jose E. Krieger 1,
Alexandre C. Pereira 1 and Paulo C. J. L. Santos 1,2*
1 Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), Faculdade de Medicina FMUSP, Universidade de
São Paulo, São Paulo, Brazil, 2Department of Pharmacology, Universidade Federal de São Paulo UNIFESP, São Paulo, Brazil
The ideal dose of the oral anticoagulant warfarin varies widely among patients, mainly
due to genetic factors. Genetic variations that impact warfarin pharmacokinetics and
the vitamin K cycle are plausible candidates for being associated with warfarin dose
requirements. Therefore, the aim of this study was to assess whether polymorphisms in
the ABCB1 and CYP4F2 genes were associated with stable warfarin dose requirements
in Brazilian patients. This retrospective study included samples from 309 individuals.
Genotyping of ABCB1 c.3435C>T and CYP4F2 c.1297G>A were performed by
polymerase chain reaction followed by melting curve analysis (HRM-PCR) and TaqMan®
genotyping assay, respectively. Stable doses were adjusted in a linear multiple regression
model for age, gender, body mass index, self-reported race, use of amiodarone,CYP2C9
(∗2 and ∗3), VKORC1 c.1639G>A, and ABCB1 c.3435C>T or CYP4F2 c.1297G>A. By
performing a univariate analysis of variance, we found that the warfarin patients who
carry ABCB1 c.3435T variant alleles (CT and TT genotypes) need fewer warfarin stable
doses in comparison with the individuals that are CC wild-type: 2.5 (p = 0.003) and
4.3 (p < 0.001) mg/week less, respectively, for the overall group of patients on stable
anticoagulation therapeutics (n = 309); and 5.5 (p = 0.006) and 10.2 (p < 0.001)
mg/week less, respectively, for the self-declared non-white stable subgroup (n = 76).
No statistically significant differences in dose requirements were observed according to
CYP4F2 genotypes. In conclusion, our results suggest ABCB1 c.3435C>T variant may
influence warfarin dose requirements in Brazilian patients, when associated with other
genotypic, demographic and clinical factors.
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INTRODUCTION
In the last 65 years, warfarin has been themost widely prescribed oral anticoagulant for treating and
preventing thromboembolic events (Barnes et al., 2015). However, due to its narrow therapeutic
index and high variance of pharmacokinetics and pharmacodynamics, warfarin interpatient
responses are largely variable. Doses of warfarin administered out of the optimal therapeutic range
commonly lead to serious adverse events, such as hemorrhagic and thromboembolic events in cases
of over and under dosage, respectively. In addition to demographic and clinical factors, such as age,
weight and use of concurrent medication, genetics is well established to play an important role in
influencing warfarin maintenance dosage among patients (Klein et al., 2009; Johnson et al., 2011).
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The key genetic variants that affect warfarin therapeutic
response are presented in theVKORC1 andCYP2C9 genes, which
encode the warfarin target enzyme and the primary warfarin
metabolizer, respectively (Lee and Klein, 2013). However, as
both these factors can explain 35–50% of the warfarin dose
variability (Lee and Klein, 2013), there has been increasing
interest in investigating additional clinically important genetic
polymorphisms that may further explain interindividual warfarin
dose variability among different populations.
Recently, studies have implicated the nonsynonymous variant
presented in the CYP4F2 gene (c.1297G>A, p.Val433Met,
rs2108622) in warfarin sensitivity (Caldwell et al., 2008; Cooper
et al., 2008; Borgiani et al., 2009; Takeuchi et al., 2009; Cen
et al., 2010; Wei et al., 2012). The CYP4F2 gene codes for the
enzyme CYP4F2 (cytochrome P450 4F2), which is responsible for
the primary metabolization of vitamin K in the liver. Warfarin
mechanism of action consists of blocking the vitamin K redox
cycle in order to diminish the concentration of the vitamin
K reduced form, which is a coactivator of several coagulation
factors (van Gorp and Schurgers, 2015). Thus, variations in the
vitamin K bioavailability are speculated to interfere in the final
response of treatment with warfarin.
Another genetic variant that has been investigated for
influencing warfarin maintenance dosage is the silent
polymorphism ABCB1 c.3435C>T (rs1045642) (Wadelius
et al., 2004; De Oliveira Almeida et al., 2011; Kim et al., 2013).
The ABCB1 gene (also called MDR1—Multidrug Resistance
1 Gene) codes for the well-known multidrug efflux pump
P-glycoprotein (P-gp), responsible for restricting the absorption
of many xenobiotics, as well as excreting them and their
metabolites through the kidneys and liver. The referred ABCB1
polymorphism has been extensively studied and associated with
the variability dosage of many drugs, including warfarin, which
is one of the many substrates of P-gp (Lepper et al., 2005; Salama
et al., 2006).
In this context, the aim of this study was to assess the
association of ABCB1 and CYP4F2 genotypes with warfarin dose
requirements in Brazilian patients.
MATERIALS AND METHODS
Study Population
This retrospective study included samples from 309 on stable
warfarin treatment, derived from a cohort of 832 Brazilian
patients enrolled between September/2011 and March/2012 at
the Heart Institute (InCor), University of São Paulo Medical
School (FMUSP), São Paulo, Brazil (Santos et al., 2015).
The study protocol was approved by the Institutional Ethics
Committee (Register Number 0804/10), and written informed
consent was obtained from all participants prior to entering the
study. Patients were categorized into self-declared “racial/color”
subgroups, according to the Brazilian Census criteria, as White,
Intermediate (meaning Brown, “Pardo” in Portuguese) or Black.
The following exclusion criteria were considered: chronic liver
failure, use of other anticoagulant drugs, receiving chemotherapy
and referred alcoholism. Personal demographic and clinical
data were obtained through a standardized interview with a
pharmacist and checked out on electronic medical records
(Santos et al., 2011a; Soares et al., 2012).
The length of time between INR tests was variable, depending
on how long the patient was presenting an INR within the target
range and the probability of events that might affect INR. In case
of target range reached, the minimum considered period between
one INR measure and another was 4 weeks. The maximum
was 12 weeks, in case of the patient was taking VKA therapy
with consistently stable INRs. These recommendations are in
accordance with anticoagulant therapy management (Holbrook
et al., 2012; Witt et al., 2016). Furthermore, over the period of
stable INR, there were no changes of the recommended weekly
dosage. Thus, we defined stable warfarin therapeutics as three
consecutive INR measures within therapeutic range (1.8–3.2),
with no need to adjust warfarin dosing.
Genotyping
Genomic DNA was extracted from peripheral blood leukocytes
by the standard salting-out method. Data of VKORC1 c.-
1639G>A (rs9923231), CYP2C9∗2 (c.430C>T, rs1799853) and
CYP2C9∗3 (c.1075A>C, rs1057910) genotypes were obtained
from the previous study of our group (Santos et al., 2015).
Genotyping of ABCB1 c.3435C>T (rs1045642) and CYP4F2
p.Val433Met (rs2108622) were performed by polymerase
chain reaction followed by melting curve analysis (HRM-
PCR) and TaqMan R© genotyping assay (Applied Biosystems,
C__16179493_40), respectively, in a Rotor-Gene Q R© (Qiagen)
(Santos et al., 2011b). All included patients (n = 309) presented
stable warfarin maintenance doses. Positive and negative
controls were added in all experiments. Furthermore, as
genotyping quality control, 6% of the samples were reanalyzed
and gave 100% data consistency.
Statistical Analysis
For descriptive analysis purposes of the cohort characteristics,
categorical variables are presented as percentages, and
continuous variables are presented as mean± standard deviation
(SD) or standard error (SE) of the mean. Chi-square and Fisher’s
exact tests were performed for comparative analysis of categorical
variables (such as Hardy–Weinberg equilibrium calculation)
according to genotypes. One-way ANOVA (analysis of variance)
test was used for analysis of warfarin stable maintenance dose
according to ABCB1 c.3435C>T (CC, CT or TT—categorized as
0, 1, and 2, respectively) and CYP4F2 c.1297G>A (GG, GA or
AA—categorized as 0, 1, and 2, respectively) genotypes.
Mean warfarin stable doses were adjusted through a linear
multiple regression model for age (years), gender (1, if male,
otherwise 0), Body Mass Index (BMI) (kg/m²), self-declared race
(white, brown or black—categorized as 1, 2, and 3, respectively),
amiodarone use (1, if the patient administers amiodarone,
otherwise 0), predicted metabolic CYP2C9 phenotypes (EM or
IM + PM—categorized as 1 or 2, respectively), and VKORC1 c.-
1639G>A genotypes (GG, GA or AA—categorized as 0, 1, and
2, respectively). Tukey’s HSD (honest significant difference) post
hoc tests were performed to identify the different groups. The
level of significance was set at p ≤ 0.05. All statistical analyses
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were carried out using SPSS statistical package (20.0 version) and
R (3.4.4 version).
RESULTS
General Characteristics of the Study
Cohort
Table 1 shows the demographic, clinical and genetic
characteristics of the patients included in the study presenting
stable warfarin treatment (n = 309). Of the 309 patients (mean
age 64 ± 14), 154 (49.8%) were female, most of them (75.4%)
declared their race/color as white, 4.6% were smokers and 10.7%
used the warfarin concurrent medication amiodarone. The
observed genotypic distributions for VKORC1 and frequencies
of CYP2C9 predicted metabolic phenotypes are shown in
Table 1. The observed required doses of warfarin ranged from
7.5 to 70mg per week (median = 27.5, mean = 28.5 ± 11.0, in
mg/week).
Supplementary Tables 1, 2 show the demographic, clinical
and genetic characteristics of the stable patients according with
ABCB1 and CYP4F2 genotypes, respectively (Supplementary
Tables 1, 2).
Frequencies of ABCB1 and CYP4F2
Polymorphisms
Table 2 summarizes the frequencies of ABCB1 and CYP4F2
genotypes of the patients. For all included stable patients
(n = 309), the frequencies of the T variant allele and of the
homozygous genotype for the ABCB1 c.3435C>T were 44 and
18.8%, respectively. The frequencies of the A variant allele
and of the homozygous genotype for the CYP4F2 c.1297G>A
were 32 and 8.7%, respectively. ABCB1 c.3435C>T and CYP4F2
c.1297G>A genotypic distributions are in accordance with
Hardy-Weinberg equilibrium (Table 2).
Mean Warfarin Dose According to ABCB1
and CYP4F2 Genotypes
By performing a univariate analysis of variance (ANOVA) for
the overall group of patients on stable warfarin treatment
(n = 309), we found different mean warfarin doses according
to ABCB1 c.3435C>T genotypes p-value (ANOVA) < 0.001;
CC: 30.5 ± 0.6 (n = 98), CT: 28.0 ± 0.5 (n = 153), TT:
26.2 ± 0.6 (n = 58) (mean stable dose ± SE in mg/week). A
Tukey’s HSD post hoc test revealed that patients with ABCB1
3435CC genotype presented higher doses than CT or TT carriers
(CC vs. TT: p < 0.001; CC vs. CT: p = 0.003; CT vs. TT:
p = 0.111). The data were adjusted for age, gender, BMI, self-
reported race/color, use of amiodarone, CYP2C9 (∗2 and ∗3), and
VKORC1 c.-1639G>A (Figure 1 and Table 3). The regression
coefficients and respective p values are shown in Supplementary
Tables 3, 4.
Additionally, we separated patients with stable dose (n= 309)
into two distinct subgroups according to self-declared race/color:
white (n = 233) and non-white (n = 76). For this analysis,
we adjusted the dose for all covariates cited above, except
self-reported race. Table 2 summarizes the frequencies of
TABLE 1 | General, clinical and genetic characteristics of the patients on stable
warfarin therapeutics (n = 309).
Variables Value
Gender, female (%) 49.8
Age (years) 64 ± 14
BMI (kg/m²) 27 ± 5
Smoking (%) 4.6
Amiodarone use (%) 10.7
Warfarin maintenance dose (mg/week) 28.5 ± 11.0
SELF-DECLARED RACE/COLOR (%)
White 75.4
Brown 17.5
Black 7.1
VKORC1 c.-1639G>A (%)
GG 49.5
GA 41.1
AA 9.4
CYP2C9 PREDICTED METABOLIC PHENOTYPES (%)
EM 72.2
IM + PM 27.8
The presented genetic frequencies are regarding CYP2C9*2 (c.430C>T, rs1799853),
CYP2C9*3 (c.1075A>C, rs1057910), and VKORC1c.-1639G>A (rs9923231)
polymorphisms. EM, Extensive metabolizer (*1/*1); IM, Intermediate metabolizer (*1/*2 or
*1/*3); PM, Poor metabolizer (*2/*2, *3/*3, or *2/*3). Continuous variables are expressed
as mean ± standard deviation. Categorical variables are presented as frequencies, in
percentage.
ABCB1 and CYP4F2 genotypes of the patients with stable
warfarin therapy according to self-declared racial subgroups
(Table 2).
For the non-white subgroup, we still found differences in
the mean warfarin doses according to ABCB1 polymorphism
p-value (ANOVA) < 0.001; CC = 35.3 ± 1.3 (n = 24),
CT = 29.8 ± 1.0 (n = 38); TT = 25.1 ± 2.0 (n = 14)
(mean stable dose ± SE in mg/week). Carriers of ABCB1
3435CC genotype presented higher doses than CT or TT,
according to Tukey’s HSD test (CC vs. TT: p < 0.001; CC
vs. CT: p = 0.006; CT vs. TT: p = 0.063) (Figure 1 and
Table 3).
Nevertheless, for the white subgroup, we have not found
differences in the mean warfarin doses according to ABCB1
polymorphism p-value (ANOVA) = 0.084; CC = 30.0 ± 0.7
(n = 74), CT = 27.3 ± 0.6 (n = 115); TT = 26.8 ± 0.7
(n= 44) (mean stable dose± SE inmg/week) (Figure 1). P values
according to Tukey’s HSD test were: CC vs. TT: p= 0.126; CC vs.
CT: p= 0.144; CT vs. TT: p= 0.867.
Regarding the CYP4F2 p.Val433Met polymorphism, we found
no significant statistical differences in the mean warfarin stable
doses among the genotypic groups p-value (ANOVA) = 0.062;
GG = 27.7 ± 0.4 (n = 156), GA = 29.3 ± 0.5 (n = 126),
AA = 28.9 ± 0.9 (n = 27). P-values according to Tukey’s HSD
test were: GG vs. AA: p = 0.567; GG vs. GA: p = 0.053; GA
vs. AA: p = 0.946. No significant differences were found when
the white subgroup was assessed p-value (ANOVA) = 0.257;
GG= 27.1± 0.6 (n= 109), GA= 28.3± 0.6 (n= 99), AA= 28.5
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TABLE 2 | Genotypic frequencies of ABCB1 and CYP4F2 polymorphisms of the patients with stable maintenance warfarin dose, according to self-declared racial
subgroups (non-white or white).
Polymorphism Overall % (n) (n = 309) Non-white % (n) (n = 76) White % (n) (n = 233) P-value*
ABCB1 c.3435C>T
CC 31.7 (98) 31.6 (24) 31.8 (74) 0.995
CT 49.5 (153) 50.0 (38) 49.4 (115)
TT 18.8 (58) 18.4 (14) 18.8 (44)
MAE (T allele) 44 43 44
HWE chi-squared test (P) 0.899 0.8779 0.954
CYP4F2 c.1297G>A
GG 50.5 (156) 61.8 (47) 46.8 (109) 0.031
GA 40.8 (126) 35.5 (27) 42.5 (99)
AA 8.7 (27) 2.7 (2) 10.7 (25)
MAE (A allele) 32 20 32
HWE chi-squared test (P) 0.828 0.412 0.722
HWE, Hardy-Weinberg equilibrium; MAE, minor allele frequency.
If HWE chi-squared test p < 0.05, there is no consistency with Hardy-Weinberg equilibrium.
*P-value of Chi-square and Fisher’s Exact tests between genotypic frequencies of non-white vs. white subgroups for ABCB1 and CYP4F2 polymorphisms, respectively.
FIGURE 1 | Warfarin dose (mg/week) according to ABCB1 genotypes in patients with stable dose. Stable maintenance dose means three consecutive INR values
within the target therapeutic range (1.8–3.2). Weekly warfarin stable doses were adjusted for age, gender, BMI, self-declared race (white, brown or black), amiodarone
use, predicted metabolic CYP2C9 phenotypes (EM or IM + PM), and VKORC1 c.-1639G>A genotypes. For the white (n = 233) and non-white (n = 76) patient
subgroups, self-declared race was not used as an independent variable. P values of ANOVA’s test are presented. Values with different superscript symbols (*, #) are
significantly different according to Tukey’s HSD post-hoc test. Statistically significant differences were set when p < 0.05.
± 1.1 (n = 25) (Supplementary Figure 1 and Supplementary
Table 5).
For the non-white subgroup we found a slight difference in
the mean warfarin doses according to CYP4F2 polymorphism:
p-value (ANOVA) = 0.048; GG = 29.2 ± 1.1 (n = 47),
GA = 33.1 ± 1.0 (n = 27), AA = 33.0 ± 1.9 (n = 2). P values
according to Tukey’s HSD test were: GG vs. AA: p = 0.705;
GG vs. GA: p = 0.042; GA vs. AA: p = 1.000. However, only
two patients were CYP4F2 1297AA carriers and self-declared
their race/color as non-white (Supplementary Figure 1 and
Supplementary Table 5).
DISCUSSION
In the present study, we found the warfarin patients who
carry ABCB1 c.3435T variant alleles (CT and TT genotypes)
need, on average, fewer warfarin stable maintenance doses in
comparison to the individuals that are wild-type CC carriers.
Similar data were obtained in the study of Wadelius et al.
They found that an ABCB1 haplotype containing only the
3435T allele as variant (called D haplotype) was over-represented
[p(χ²) = 0.0242] among the low warfarin dose patients (<0.33
mg/kg, 60%) subgroup in comparison to the medium dose
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TABLE 3 | Predicted warfarin doses by the multiple linear regression models adjusted with ABCB1 genotypes for overall, white and non-white patients’ subgroups.
Subgroups ABCB1 c.3435C>T genotypes Mean predicted dose (mg/week) SE 95% CI P-value
Overall (n = 309) CC 30.5 0.6 29.3 31.7 <0.001
CT 28.0 0.5 27.1 29.0
TT 26.2 0.6 25.0 27.5
Non-white (n = 76) CC 35.3 1.3 32.6 38.0 <0.001
CT 29.8 1.0 27.7 31.9
TT 25.1 2.0 20.8 29.3
White (n = 233) CC 30.0 0.7 27.5 30.4 0.084
CT 27.3 0.6 26.1 28.5
TT 26.8 0.7 25.4 28.1
(0.33–0.46 mg/kg, 25%) and the high dose (>0.46 mg/kg, 15%)
subgroups (p= 0.0094). On average, the patients that carried one
3435T variant allele for the D haplotype (n = 20) needed 24%
lower warfarin dose and dose/body weight (BW) than the other
patients (n = 181) who did not carry this haplotype (Wadelius
et al., 2004).
In addition, Kim et al. found that patients with ABCB1
c.3435TT genotypes needed, descriptively, the lowest dose of
warfarin compared with those with the other 2 genotypes
(warfarin dose (mg/week): CC: 59.5 (n= 70); CT: 56.9 (n= 90);
TT: 55.6 (n= 36). Nevertheless, no statistical differences between
the genotypic subgroups were found. However, according to
race, it is possible to verify that the African, Hispanic, and
Asian Americans (the non-white subgroup in Kim’s study),
when analyzed together presented a decreasing pattern of mean
warfarin doses according to the addition of the 3435T allele
(Kim et al., 2013). The authors considered that the study had
little statistical power due to a small number of patients in
some genotypic subgroups. Likewise, other studies have also
failed to find statistically significant association between ABCB1
c.3435C>T and warfarin dose requirements (Takeuchi et al.,
2009; Issac et al., 2014).
Contrary to our result, a Brazilian study of De Oliveira
Almeida et al. found that the ABCB1 c.3435T variant allele
contributes to higher warfarin doses in thrombophilic patients
(De Oliveira Almeida et al., 2011; de Oliveira Almeida et al.,
2014). This finding was exclusively seen for the subgroup of
patients who needed up to 70mg of weekly warfarin dose. It is
valid to point out that in the study of De Oliveira Almeida et al.
the frequency of the T allele was very high (66%) in comparison
to the reported ABCB1 c.3435C>T polymorphism frequency in
other Brazilian studies, including the present one (around 40%)
(Scheiner et al., 2010; Santos et al., 2011a). Furthermore, the
patients were categorized into two subgroups: those receiving
more and those receiving less than 70mg warfarin weekly dose,
which differs from the methodology of analysis of the present
study.
In the literature, the studies that aimed to investigate the
effect of the ABCB1 c.3435C>T polymorphism on the codified
P-glycoprotein (P-gp) are quite controversial (Fromm, 2002;
Sakaeda et al., 2003; Lepper et al., 2005). Some studies have
reported pronounced efflux of substrate and higher mRNA
expression of P-gp in the gastrointestinal tract in 3435CC carriers
in comparison to 3435CT or 345TT (Greiner et al., 1999;
Hoffmeyer et al., 2000), while other studies have found that these
parameters are significantly lower in the wild-type individuals
(Moriya et al., 2002; Nakamura et al., 2002; Morita et al., 2003).
In other words, some studies have observed that the ABCB1
c.3435C>T polymorphism leads to augmented P-gp function or
expression, although other studies have found that this variant
causes decreased or loss of P-gp activity (Hoffmeyer et al., 2000;
Hitzl et al., 2001; Kim et al., 2001; Sakaeda et al., 2003; Kimchi-
Sarfaty et al., 2007). However, these studies were not performed
with the same substrates and populations. So, it is likely that
the effect of the ABCB1 c.3435C>T polymorphism on the P-gp
activity depends on the substrate-specificity and environmental
factors (Perloff et al., 2001; Lepper et al., 2005).
Moreover, the biological assumptions about how the ABCB1
c.3435C>T polymorphism affect P-gp are diverse. Despite the
fact that this polymorphism is a silent mutation, as it does
not lead to change of the codified isoleucine amino acid at
position 1145, Kimchi-Sarfaty et al. have hypothesized that
this variant may lead to a conformational P-gp change, which
may affect the substrate specificity, explaining the observed
affected efflux-pump function (Kimchi-Sarfaty et al., 2007).
This conformational change could be due to distinct timing
of cotranslational folding of the codon containing the variant.
Furthermore, other so far unidentified variants that are in linkage
disequilibrium with the c.3435C>T polymorphism, presented
in control expression regions (e.g., promoter, enhancer) of
the ABCB1 gene, may influence P-gp expression (Hoffmeyer
et al., 2000; Frittitta et al., 2001). Additionally, as the ABCB1
c.3435C>T is in strong linkage disequilibrium with the non-
synonymous c.2677T>G (p.Ser893Ala) and the synonymous
c.1236T>C (p.Gly412=) variants, some authors hypothesize that
the c.3435C>T itself does not directly influence the P-gp activity,
but this common haplotype does (Salama et al., 2006; Saraeva
et al., 2007).
We suggest that a possible biological explanation for
our finding regarding the impact of ABCB1 c.3435C>T
polymorphism in the warfarin dose requirements is that the
rs1045642 variant allele leads to an altered P-gp fold, affecting
the warfarin site of recognition, and therefore leads to decreased
warfarin efflux activity. It would cause augmented warfarin
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bioavailability and therefore lower warfarin doses would be
required for those patients who are CT and TT carriers.
Our study presents the following limitation: we did not
assess the genetic ancestry of the patients. Instead, we used the
self-declared race/color parameter, categorized according to the
Brazilian Census IBGE (Brazilian Institute of Geography and
Statistics) criteria. Self-declared race/color does not correlate
completely with genetic ancestry in Brazilians (Pena et al.,
2011), as the self-perception of color/race in Brazil is primarily
accounted for by phenotypic characteristics, as well as socio,
cultural and geographic factors into which the subject is inserted
(Santos et al., 2009). However, this parameter is useful in the
real-life setting.
The association between ABCB1 c.3435C>T and warfarin
dose requirements, the main finding of this study, was observed
for the overall stable group and non-white self-declared subgroup
of patients, but not for those who self-declared their race/color
as white. So, the above cited limitation might be, at least
partially, contributing to this lack of association. The c.3435T
variant allele in the ABCB1 gene is frequently rarer in brown
and black than in white people (Santos et al., 2011a; Soares
et al., 2012). However, in the study of Kim et al. the P-gp
function was found to be similar, on average, in European
Americans and African Americans, for example (Kim et al.,
2001). Thus, further studies are needed to elucidate the
specific impact of the ABCB1 c.3435C>T polymorphism in
non-whites.
Regarding the lack of association of the CYP4F2 c.1297G>A
polymorphism with warfarin dose requirements in the present
study, when this variant was included as a covariate in a
multiple-regression analysis along with other relevant clinical
(age, gender, BMI, self-declared race, amiodarone use) and
genetic factors (VKORC1 and CYP2C9 genotypes), it did not
contribute significantly to the model, even when self-declared
race/color subgroups were assessed. Nevertheless, we verified
a descriptive bias of augmented dose in individuals that carry
the polymorphic allele A, but with no statistical significance
(corresponding to GA and AA genotypes): GG = 27.7 ± 0.4
(n = 156), GA =2 9.3 ± 0.5 (n = 126), AA = 28.9 ± 0.9
(n= 27).
Through a genome wide association study (GWAS), Caldwell
et al. implicated the CYP4F2 c.1297G>A polymorphism as a
minor significant influencer of warfarin dose variability. The
authors found that in three independent cohorts of white patients
who had a stable warfarin dose (n = 1,009), the CYP4F2
c.1297G>A variant contributed to approximately 1mg/day more
in homozygous AA individuals, when compared to wild-type
(Caldwell et al., 2008). Other studies reported similar results
(Zhang et al., 2009; Perini et al., 2010; Botton et al., 2011).
In conclusion, our results suggest ABCB1 c.3435C>T
polymorphism may marginally influence warfarin dose
requirements in Brazilian patients, when associated with
other genotypic, demographic and clinical factors.
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